Policy & Regulation
Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
18 September 2019 - - US-based biotechnology company Genentech, a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY), has presented longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showing that patients who were treated with Ocrevus (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS and primary progressive MS, the company said.

These results suggest earlier treatment with Ocrevus reduced the risk of disability progression and this effect was sustained over time.

Additionally, new safety data as of January 2019 were announced, representing 4,611 patients with RMS and PPMS and 14,329 patient years of exposure to Ocrevus, across all Ocrevus clinical trials, and remain consistent with the medicine's favorable benefit-risk profile.

Findings were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm.

In the OPERA OLE, the proportion of RMS patients with 24-week confirmed disability progression was lower for those treated with continuous Ocrevus (total of six years on Ocrevus) compared with patients who switched to Ocrevus after two years of interferon beta-1a treatment in the double-blind period (total of four years on Ocrevus) (19% vs. 24%; p